18F-FDG PET/CT impact on testicular tumours clinical management

Ambrosini, Valentina; Zucchini, G; Nicolini, Silvia; Berselli, Annalisa; Nanni, Cristina; Allegri, Vincenzo; Martoni, Andrea; Rubello, Domenico; Cricca, A.; Fanti, Stefano

doi:10.1007/s00259-013-2624-3

Cited by 59 publications

(39 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18 F-FDG PET/CT analysis showed sensitivity, specificity, PPV, NPV and accuracy of 94.2%, 75.0%, 83.0%, 90.9% and 85.8%, respectively. These results correlate with the recently published study by Ambrosini et al 21 The specificity was, however, on the lower side, possibly because of the higher prevalence of infective/ inflammatory pathology in our patient population from a developing country. A recent study by Ambrosini et al 21 showed…”

Section: Periodic Measurement Of Serum Tumour Markers (Afp B-hcg Andsupporting

confidence: 81%

“…However, it can even detect disease in patients with normal tumour markers. 21 In the present study population, 18 F-FDG PET/CT demonstrated recurrent lesions in nine patients with normal serum tumour markers. In the backdrop of known limitations of tumour markers for detection of recurrent disease in GCTs, this finding assumes important clinical significance.…”

Section: Periodic Measurement Of Serum Tumour Markers (Afp B-hcg Andmentioning

confidence: 94%

“…The inflammatory lesions resulting in FP 18 F-FDG PET/CT results have also been documented in results published by other groups. 9,21 Hence, when there is discrepancy between tumour markers and PET/CT findings, tissue diagnosis should be obtained. Three patients in the present study had FN PET/CT results.…”

Section: Periodic Measurement Of Serum Tumour Markers (Afp B-hcg Andmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic accuracy of integrated¹⁸F-FDG PET/CT for restaging patients with malignant germ cell tumours

Sharma¹,

Jain²,

Parida³

et al. 2014

BJR

View full text Add to dashboard Cite

Objective: Evaluation of utility of fluorine-18 fludeoxyglucose ( 18 F-FDG) positron emission tomography/CT (PET/CT) for restaging patients with primary malignant germ cell tumours (GCTs). Methods: Data of 92 patients (age, 31.94 6 10.1 years; male/ female, 86/6) with histopathologically confirmed malignant GCTs (gonadal, 88; mediastinal, 4; seminomatous, 47 and non-seminomatous, 45) who underwent 18 F-FDG PET/CT for restaging (suspected recurrence/post-therapy evaluation) were retrospectively analysed. Two experienced nuclear medicine physicians reviewed the PET/CT images in consensus, qualitatively and semi-quantitatively [maximum standardized uptake value (SUVmax)]. Histopathology (if available) and clinical/imaging/biochemical follow-up (minimum of 6 months) were employed as the reference standard. Results:18 F-FDG PET/CT was interpreted as positive in 59 and negative in 33 patients. Local disease was seen in 5, nodal disease in 50 and distant metastasis in 22 patients. PET/CT was true positive in 49, false positive in 10, true negative in 30 and false negative in 3 patients. 18F-FDG PET/CT showed sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 94.2%, 75.0%, 83.0%, 90.9% and 85.8% overall; 90.0%, 74.0%, 72.0%, 90.9% and 80.8% in seminomatous GCT; and 96.8%, 76.9%, 91.1%, 90.9% and 91.1% in non-seminomatous GCT, respectively. Difference in PET/CT accuracy for seminomatous and non-seminomatous GCTs was not significant (p 5 0.263). PET/CT demonstrated disease in 13 patients with negative/equivocal conventional imaging findings and in 9 patients with normal tumour markers. No site-or histology-based difference was seen in SUVmax. Conclusion:18 F-FDG PET/CT demonstrates high diagnostic accuracy for restaging patients with malignant GCTs. It has comparable diagnostic performance in both seminomatous and non-seminomatous malignant GCTs. Advances in knowledge:The present article demonstrates high diagnostic accuracy of 18 F-FDG PET/CT for restaging both seminomatous and non-seminomatous malignant GCTs in a large patient population.Germ cell tumour (GCT) is the commonest malignancy in males aged between 20 and 35 years.1 With cisplatin-based chemotherapy, high long-term cure rates can be achieved in patients with GCTs.2 Traditionally, the follow-up of patients with GCT is carried out with clinical examination, measurement of serum tumour markers [alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (b-HCG) and lactate dehydrogenase (LDH)], and with conventional imaging investigations such as CT or MRI.3 A major issue in the management of GCTs is post-chemotherapy residual masses, which harbour viable tumour cells in about 11-37% of cases. 4 Unfortunately, CT or MRI cannot predict the histology of residual masses and has limited specificity in post-therapy setting.5

show abstract

Section: Periodic Measurement Of Serum Tumour Markers (Afp B-hcg Andsupporting

confidence: 81%

Section: Periodic Measurement Of Serum Tumour Markers (Afp B-hcg Andmentioning

confidence: 94%

Section: Periodic Measurement Of Serum Tumour Markers (Afp B-hcg Andmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic accuracy of integrated¹⁸F-FDG PET/CT for restaging patients with malignant germ cell tumours

Sharma¹,

Jain²,

Parida³

et al. 2014

BJR

View full text Add to dashboard Cite

show abstract

“…In one study, 70% of patients with normal-sized nodes who subsequently developed relapse could be identified at presentation by the use of PET 69 . Recently, Ambrosini et al, performed a retrospective study in 51 seminoma and 70 NSGCT 72 . FDG demonstrated good sensitivity and specificity for seminoma lesions (92% and 84%, respectively), but its sensitivity was lower for NSGCT (sensitivity and specificity were 77% and 95%, respectively).…”

Section: Use Of Pet In Testicular Cancermentioning

confidence: 99%

“…For many years, FDG PET has been considered as the gold standard for discriminating between residual tumors and necrosis/fibrosis (Fig 6). Several prospective and retrospective studies evaluated the diagnostic performance of FDG-PET or PET/CT in the post chemotherapy management of patients with GCT 70,72,75–84 . Recently, Treglia et al published a meta-analysis about the diagnostic performance of FDG PET and PET/CT in the post chemotherapy management of patients with seminoma 85 .…”

Section: Use Of Pet In Testicular Cancermentioning

confidence: 99%

PET/Computed Tomography in Renal, Bladder, and Testicular Cancer

Bouchelouche¹,

Choyke²

2015

PET Clinics

View full text Add to dashboard Cite

Imaging plays an important role in the clinical management of cancer patients. Hybrid imaging with PET/CT is having a broad impact in oncology, and in recent years PET/CT is beginning to have an impact in uro-oncology as well. In both bladder and renal cancer there is a need to study the efficacy of other tracers than F-18 fluorodeoxyglucose (FDG), particularly tracers with only limited renal excretion. Thus, new tracers are being introduced in these malignancies. This review focuses on the clinical role of FDG and other PET agents in renal, bladder and testicular cancer.

show abstract

T Staging and Target Volume Definition by Imaging in GU Tumors

Castelluci

Fanti

Bracci

et al. 2020

Imaging and Interventional Radiology for Radiation Oncology

View full text Add to dashboard Cite

18F-FDG PET/CT impact on testicular tumours clinical management

Abstract: Our preliminary data demonstrate the potential usefulness of PET/CT for the assessment of patients with testicular tumour. It provides valuable information for the clinical management, particularly for clinical surveillance, post-therapy assessment and when relapse is suspected.

Cited by 59 publications

References 20 publications

Diagnostic accuracy of integrated¹⁸F-FDG PET/CT for restaging patients with malignant germ cell tumours

Diagnostic accuracy of integrated¹⁸F-FDG PET/CT for restaging patients with malignant germ cell tumours

PET/Computed Tomography in Renal, Bladder, and Testicular Cancer

T Staging and Target Volume Definition by Imaging in GU Tumors

Contact Info

Product

Resources

About

18F-FDG PET/CT impact on testicular tumours clinical management

Abstract: Our preliminary data demonstrate the potential usefulness of PET/CT for the assessment of patients with testicular tumour. It provides valuable information for the clinical management, particularly for clinical surveillance, post-therapy assessment and when relapse is suspected.

Cited by 59 publications

References 20 publications

Diagnostic accuracy of integrated18F-FDG PET/CT for restaging patients with malignant germ cell tumours

Diagnostic accuracy of integrated18F-FDG PET/CT for restaging patients with malignant germ cell tumours

PET/Computed Tomography in Renal, Bladder, and Testicular Cancer

T Staging and Target Volume Definition by Imaging in GU Tumors

Contact Info

Product

Resources

About

Diagnostic accuracy of integrated¹⁸F-FDG PET/CT for restaging patients with malignant germ cell tumours

Diagnostic accuracy of integrated¹⁸F-FDG PET/CT for restaging patients with malignant germ cell tumours